Inclusion Criteria:

          1. Provision of signed and dated, written informed consent form prior to any mandatory
             study specific procedures..

          2. Female Subjects with ≥ 18 years of age

          3. Subjects receiving olaparib for the following indications in ovarian cancer:

             for the maintenance treatment of adult subjects with recurrent epithelial ovarian,
             fallopian tube or primary peritoneal cancer, who are in a complete or partial response
             to platinum-based chemotherapy

          4. Subjects receiving olaparib for the following indication in breast cancer:

        in subjects with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic
        breast cancer who have previously been treated with chemotherapy in the neoadjuvant,
        adjuvant or metastatic setting. Subjects with HR-positive breast cancer should have been
        treated with a prior endocrine therapy or be considered inappropriate for endocrine
        treatment

        Exclusion Criteria:

          1. Patients with either the history of hypersensitivity to excipients of the study drug
             or to drugs with a similar chemical structure or class to the study drug.

          2. pregnant and/or lactating women.

          3. Patients with a previously or currently diagnosed MDS/ AML or pneumonitis.

          4. Patients who have not recovered sufficiently from prior surgery or anticancer
             treatment.

          5. Patients who have known history of hepatitis B or hepatitis C

          6. Patients with active infection such as TB.

          7. Participation in another clinical study with a study drug administered in the last 3
             months